Language

English

Publication Date

3-17-2026

Journal

The Journal of Infectious Diseases

DOI

10.1093/infdis/jiaf571

PMID

41313671

PMCID

PMC13017142

PubMedCentral® Posted Date

11-28-2025

PubMedCentral® Full Text Version

Post-print

Abstract

This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 × 105 TCID50 dose was superior to the 5 × 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.

Keywords

Humans, Double-Blind Method, Adult, Male, Chikungunya Fever, Chikungunya virus, Female, Antibodies, Viral, Middle Aged, Young Adult, Viral Vaccines, Measles virus, Immunogenicity, Vaccine, Adolescent, Healthy Volunteers, chikungunya, vaccine, phase 1 trial, measles-vectored vaccine

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.